[
  {
    "question": {
      "question_id": "cs03_q01_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 12,
      "question_type": "longitudinal",
      "prompt": "Based on the trial data so far, are there any emerging safety signals in the lab panels?",
      "ground_truth": {
        "canonical_answer": "ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q01_longitudinal",
      "answer_text": "Based on the trial data summaries retrieved, there are emerging safety signals in the lab panels, though they are currently classified as low density. Episodes from May 2024 (e.g., clinical_signal_03_ep_011, clinical_signal_03_ep_010, clinical_signal_03_ep_012, clinical_signal_03_ep_009) indicate a shift from baseline to an \"early_signal\" phase with \"low\" signal density, suggesting the presence of preliminary laboratory abnormalities warranting monitoring [clinical_signal_03_ep_011][clinical_signal_03_ep_010][clinical_signal_03_ep_012][clinical_signal_03_ep_009]. Earlier reports from March and April 2024 showed no significant signals, remaining in the \"baseline\" phase with \"none\" signal density [clinical_signal_03_ep_004][clinical_signal_03_ep_005][clinical_signal_03_ep_008]. While specific lab values are not detailed in the summaries, the consistent upgrade in signal phase and density during May indicates emerging laboratory-related safety concerns.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_a49f4c1bacdb46768cf10baf",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 752
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_a49f4c1bacdb46768cf10baf",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_038af9fc2d0e47e4ad1cff7a",
              "name": "memory_search",
              "arguments": {
                "query": "emerging safety signals lab panels trial data",
                "filters": {}
              }
            }
          ],
          "tokens_used": 1053
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_038af9fc2d0e47e4ad1cff7a",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_008\", \"text\": \"## 2024-04-22 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 180\\n- Active: 177\\n- Screen Failures Cumulative: 13\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 13\\n- Site 02 Active: 13\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 16\\n- Site 03 Active: 16\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.03200204813108039, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.031544957774465976, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.03125763125763126, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_010\", \"text\": \"## 2024-05-06 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 184\\n- Active: 182\\n- Screen Failures Cumulative: 20\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.030679156908665108, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 120\\n- Active: 118\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 12\\n- Site 01 Active: 12\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 9\\n- Site 02 Active: 9\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 11\\n- Site 03 Active: 11\\n- Site 03 Statin Concomitant: 3\\n- Site 04 Enrolled: 8\\n- Site 04 Active: 8\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 10\\n- Site 05 A\", \"score\": 0.030330882352941176, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_012\", \"text\": \"## 2024-05-20 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 186\\n- Screen Failures Cumulative: 21\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030117753623188408, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.030017921146953404, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_79d2fe4d29a84268a58747ac",
              "name": "batch_retrieve",
              "arguments": {
                "ref_ids": [
                  "clinical_signal_03_ep_008",
                  "clinical_signal_03_ep_004",
                  "clinical_signal_03_ep_011",
                  "clinical_signal_03_ep_010",
                  "clinical_signal_03_ep_005",
                  "clinical_signal_03_ep_012",
                  "clinical_signal_03_ep_009"
                ]
              }
            }
          ],
          "tokens_used": 3239
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_79d2fe4d29a84268a58747ac",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "Based on the trial data summaries retrieved, there are emerging safety signals in the lab panels, though they are currently classified as low density. Episodes from May 2024 (e.g., clinical_signal_03_ep_011, clinical_signal_03_ep_010, clinical_signal_03_ep_012, clinical_signal_03_ep_009) indicate a shift from baseline to an \"early_signal\" phase with \"low\" signal density, suggesting the presence of preliminary laboratory abnormalities warranting monitoring [clinical_signal_03_ep_011][clinical_signal_03_ep_010][clinical_signal_03_ep_012][clinical_signal_03_ep_009]. Earlier reports from March and April 2024 showed no significant signals, remaining in the \"baseline\" phase with \"none\" signal density [clinical_signal_03_ep_004][clinical_signal_03_ep_005][clinical_signal_03_ep_008]. While specific lab values are not detailed in the summaries, the consistent upgrade in signal phase and density during May indicates emerging laboratory-related safety concerns.",
          "tokens_used": 3513
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8557,
      "wall_time_ms": 14480.583194992505,
      "budget_violations": [
        "Cumulative result token limit exceeded: 7606 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_011",
        "clinical_signal_03_ep_010",
        "clinical_signal_03_ep_012",
        "clinical_signal_03_ep_009",
        "clinical_signal_03_ep_004",
        "clinical_signal_03_ep_005",
        "clinical_signal_03_ep_008"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_010",
      "clinical_signal_03_ep_012",
      "clinical_signal_03_ep_009",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_005",
      "clinical_signal_03_ep_008"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_010",
      "clinical_signal_03_ep_012",
      "clinical_signal_03_ep_009",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_005",
      "clinical_signal_03_ep_008"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q02_null",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 12,
      "question_type": "null_hypothesis",
      "prompt": "What was the enrollment count at Site 03 in the Week 6 summary?",
      "ground_truth": {
        "canonical_answer": "The enrollment figure as documented in the Week 6 site summary.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006"
        ],
        "key_facts": []
      }
    },
    "answer": {
      "question_id": "cs03_q02_null",
      "answer_text": "The provided search results do not contain a \"Week 6 summary.\" However, they do include daily operations summaries with enrollment data for Site 03 on various dates. The closest date to what might be Week 6 is the summary from **2024-04-22** (clinical_signal_03_ep_008), which reports that **Site 03 had 16 enrolled participants** [clinical_signal_03_ep_008].\n\nSince no explicit \"Week 6\" document is identified, this is the best available match based on the timeline.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_9270804d5ca14e9e95d920d7",
              "name": "memory_search",
              "arguments": {
                "query": "Week 6 summary Site 03 enrollment count",
                "filters": {}
              }
            }
          ],
          "tokens_used": 769
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_9270804d5ca14e9e95d920d7",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_008\", \"text\": \"## 2024-04-22 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 180\\n- Active: 177\\n- Screen Failures Cumulative: 13\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 13\\n- Site 02 Active: 13\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 16\\n- Site 03 Active: 16\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.032018442622950824, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 80\\n- Active: 80\\n- Screen Failures Cumulative: 5\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 8\\n- Site 01 Active: 8\\n- Site 01 Statin Concomitant: 2\\n- Site 02 Enrolled: 6\\n- Site 02 Active: 6\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 7\\n- Site 03 Active: 7\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 5\\n- Site 04 Active: 5\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 6\\n- Site 05 Active: 6\", \"score\": 0.03200204813108039, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 120\\n- Active: 118\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 12\\n- Site 01 Active: 12\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 9\\n- Site 02 Active: 9\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 11\\n- Site 03 Active: 11\\n- Site 03 Statin Concomitant: 3\\n- Site 04 Enrolled: 8\\n- Site 04 Active: 8\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 10\\n- Site 05 A\", \"score\": 0.031009615384615385, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.0304147465437788, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_010\", \"text\": \"## 2024-05-06 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 184\\n- Active: 182\\n- Screen Failures Cumulative: 20\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.03028233151183971, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 60\\n- Active: 60\\n- Screen Failures Cumulative: 4\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 6\\n- Site 01 Active: 6\\n- Site 01 Statin Concomitant: 1\\n- Site 02 Enrolled: 4\\n- Site 02 Active: 4\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 5\\n- Site 03 Active: 5\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 4\\n- Site 04 Active: 4\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 5\\n- Site 05 Active: 5\", \"score\": 0.03007688828584351, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.029957522915269395, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The provided search results do not contain a \"Week 6 summary.\" However, they do include daily operations summaries with enrollment data for Site 03 on various dates. The closest date to what might be Week 6 is the summary from **2024-04-22** (clinical_signal_03_ep_008), which reports that **Site 03 had 16 enrolled participants** [clinical_signal_03_ep_008].\n\nSince no explicit \"Week 6\" document is identified, this is the best available match based on the timeline.",
          "tokens_used": 2955
        }
      ],
      "tool_calls_made": 1,
      "total_tokens": 3724,
      "wall_time_ms": 5916.827708017081,
      "budget_violations": [],
      "refs_cited": [
        "clinical_signal_03_ep_008"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_008"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_008"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q13_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 12,
      "question_type": "paraphrase",
      "prompt": "Are any laboratory parameters trending outside normal limits in specific patient populations?",
      "ground_truth": {
        "canonical_answer": "ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q13_paraphrase",
      "answer_text": "Yes, laboratory parameters are trending outside normal limits in the statin subgroup patient population, particularly for liver enzymes.\n\nAlanine aminotransferase (ALT), a marker of liver function, shows a clear upward trend over time. In early March 2024, ALT levels were within normal range, with mean values between 24.6 and 26.8 U/L [clinical_signal_03_ep_002, clinical_signal_03_ep_003, clinical_signal_03_ep_004]. By late April to mid-May 2024, mean ALT levels increased to 32.3 U/L [clinical_signal_03_ep_009] and further rose to 47.6 U/L [clinical_signal_03_ep_011], approaching or exceeding the upper limit of normal (typically around 40\u201350 U/L). Similarly, aspartate aminotransferase (AST) levels also increased from a mean of 22.1 U/L in March [clinical_signal_03_ep_002] to 35.8 U/L in May [clinical_signal_03_ep_011].\n\nThese rising trends in ALT and AST suggest potential hepatocellular stress or injury in this patient subgroup, warranting further clinical evaluation.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_515286b552f04bbda396c6bd",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 746
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_515286b552f04bbda396c6bd",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_2e05729303de468b9ece7d90",
              "name": "memory_search",
              "arguments": {
                "query": "laboratory parameters abnormal trends in patient populations",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1048
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_2e05729303de468b9ece7d90",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 52\\n- ALT (U/L) Mean: 24.6\\n- ALT (U/L) Median: 23.8\\n- AST (U/L) Mean: 23.6\\n- AST (U/L) Median: 23.2\\n- Bilirubin (mg/dL) Mean: 0.86\\n- Bilirubin (mg/dL) Median: 0.84\\n- ALP (U/L) Mean: 73.7\\n- ALP (U/L) Median: 63.8\\n- Creatinine (mg/dL) Mean: 1.06\\n- Creatinine (mg/dL) Median: 0.92\\n- BUN (mg/dL) Mean: 13.3\\n- BUN (mg/dL) Median: 13.0\\n- WBC (K) Mean: 8.2\\n- WBC (K) Median: 5.5\\n- Platelets (K) Mean: 235\\n- Platelets (K) Median:\", \"score\": 0.03278688524590164, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 54\\n- ALT (U/L) Mean: 32.3\\n- ALT (U/L) Median: 31.9\\n- AST (U/L) Mean: 31.2\\n- AST (U/L) Median: 31.2\\n- Bilirubin (mg/dL) Mean: 0.56\\n- Bilirubin (mg/dL) Median: 0.56\\n- ALP (U/L) Mean: 66.5\\n- ALP (U/L) Median: 70.2\\n- Creatinine (mg/dL) Mean: 0.96\\n- Creatinine (mg/dL) Median: 0.83\\n- BUN (mg/dL) Mean: 17.3\\n- BUN (mg/dL) Median: 11.3\\n- WBC (K) Mean: 6.9\\n- WBC (K) Median: 7.6\\n- Platelets (K) Mean: 238\\n- Platelets (K) Median:\", \"score\": 0.03252247488101534, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 55\\n- ALT (U/L) Mean: 47.6\\n- ALT (U/L) Median: 47.4\\n- AST (U/L) Mean: 35.8\\n- AST (U/L) Median: 34.3\\n- Bilirubin (mg/dL) Mean: 0.7\\n- Bilirubin (mg/dL) Median: 0.67\\n- ALP (U/L) Mean: 67.5\\n- ALP (U/L) Median: 61.8\\n- Creatinine (mg/dL) Mean: 0.8\\n- Creatinine (mg/dL) Median: 0.86\\n- BUN (mg/dL) Mean: 13.5\\n- BUN (mg/dL) Median: 15.1\\n- WBC (K) Mean: 6.7\\n- WBC (K) Median: 5.6\\n- Platelets (K) Mean: 258\\n- Platelets (K) Median: 2\", \"score\": 0.032266458495966696, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup N: 53\\n- Statin Subgroup ALT (U/L) Mean: 26.8\\n- Statin Subgroup ALT (U/L) Median: 26.3\\n- Statin Subgroup AST (U/L) Mean: 22.1\\n- Statin Subgroup AST (U/L) Median: 20.8\\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.73\\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.72\\n- Statin Subgroup ALP (U/L) Mean: 71.0\\n- Statin Subgroup ALP (U/L) Median: 75.0\\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.85\\n- Statin Subgroup Creatinine (mg/dL) M\", \"score\": 0.032018442622950824, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup N: 55\\n- Statin Subgroup ALT (U/L) Mean: 26.0\\n- Statin Subgroup ALT (U/L) Median: 24.3\\n- Statin Subgroup AST (U/L) Mean: 27.9\\n- Statin Subgroup AST (U/L) Median: 25.9\\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.59\\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.56\\n- Statin Subgroup ALP (U/L) Mean: 79.3\\n- Statin Subgroup ALP (U/L) Median: 57.2\\n- Statin Subgroup Creatinine (mg/dL) Mean: 1.04\\n- Statin Subgroup Creatinine (mg/dL) M\", \"score\": 0.03177805800756621, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_008\", \"text\": \"## 2024-04-22 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 52\\n- ALT (U/L) Mean: 25.0\\n- ALT (U/L) Median: 22.3\\n- AST (U/L) Mean: 20.6\\n- AST (U/L) Median: 19.0\\n- Bilirubin (mg/dL) Mean: 0.73\\n- Bilirubin (mg/dL) Median: 0.7\\n- ALP (U/L) Mean: 73.1\\n- ALP (U/L) Median: 76.4\\n- Creatinine (mg/dL) Mean: 0.81\\n- Creatinine (mg/dL) Median: 0.83\\n- BUN (mg/dL) Mean: 15.6\\n- BUN (mg/dL) Median: 12.5\\n- WBC (K) Mean: 6.0\\n- WBC (K) Median: 6.3\\n- Platelets (K) Mean: 242\\n- Platelets (K) Median: \", \"score\": 0.031544957774465976, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_010\", \"text\": \"## 2024-05-06 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 54\\n- ALT (U/L) Mean: 37.2\\n- ALT (U/L) Median: 35.2\\n- AST (U/L) Mean: 32.1\\n- AST (U/L) Median: 30.9\\n- Bilirubin (mg/dL) Mean: 0.68\\n- Bilirubin (mg/dL) Median: 0.65\\n- ALP (U/L) Mean: 65.1\\n- ALP (U/L) Median: 62.3\\n- Creatinine (mg/dL) Mean: 1.09\\n- Creatinine (mg/dL) Median: 0.88\\n- BUN (mg/dL) Mean: 17.8\\n- BUN (mg/dL) Median: 16.4\\n- WBC (K/\\u00b5L) Mean: 6.3\\n- WBC (K/\\u00b5L) Median: 6.7\\n- Platelets (K/\\u00b5L) Mean: 245\\n- Platelets (K\", \"score\": 0.03131881575727918, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_ad0324947cea47919f688502",
              "name": "batch_retrieve",
              "arguments": {
                "ref_ids": [
                  "clinical_signal_03_ep_004",
                  "clinical_signal_03_ep_009",
                  "clinical_signal_03_ep_011",
                  "clinical_signal_03_ep_002",
                  "clinical_signal_03_ep_003",
                  "clinical_signal_03_ep_008",
                  "clinical_signal_03_ep_010"
                ]
              }
            }
          ],
          "tokens_used": 3435
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_ad0324947cea47919f688502",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "Yes, laboratory parameters are trending outside normal limits in the statin subgroup patient population, particularly for liver enzymes.\n\nAlanine aminotransferase (ALT), a marker of liver function, shows a clear upward trend over time. In early March 2024, ALT levels were within normal range, with mean values between 24.6 and 26.8 U/L [clinical_signal_03_ep_002, clinical_signal_03_ep_003, clinical_signal_03_ep_004]. By late April to mid-May 2024, mean ALT levels increased to 32.3 U/L [clinical_signal_03_ep_009] and further rose to 47.6 U/L [clinical_signal_03_ep_011], approaching or exceeding the upper limit of normal (typically around 40\u201350 U/L). Similarly, aspartate aminotransferase (AST) levels also increased from a mean of 22.1 U/L in March [clinical_signal_03_ep_002] to 35.8 U/L in May [clinical_signal_03_ep_011].\n\nThese rising trends in ALT and AST suggest potential hepatocellular stress or injury in this patient subgroup, warranting further clinical evaluation.",
          "tokens_used": 3744
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8973,
      "wall_time_ms": 15505.658430978656,
      "budget_violations": [
        "Cumulative result token limit exceeded: 7820 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_009",
        "clinical_signal_03_ep_011",
        "clinical_signal_03_ep_002"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_009",
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_002"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_009",
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_002"
    ]
  }
]